Wusterhausens insights on future peptides for weight loss/metabolism As always, thanks for watching
Your provider will recommend an optimal frequency based on your bodys response and goals
New JAMA Study Links Wegovy to NAION A JAMA study published on July 3, 2024, on the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide found an increased risk of the condition in patients taking semaglutide compared to those taking non-GLP-1 RA medications
Kurowska-Stolarska M, Alivernini S
In this regard, DPP-IV can be either overexpressed or underexpressed in human solid tumor tissues, suggesting the possible role of DPP-IV as a potential diagnostic marker and therapeutic target in solid tumors (Havre et al., 2008)
Keep in mind that finding the right medication might require some trial and error, and your provider will guide you through this process to identify the most effective and safe option for your weight loss journey